Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.

Journal of cardiovascular pharmacology - 1 Oct 2021

Black Donald M, Miller Michael, Heinonen Therese M, Zhang Guili

Abstract excerpt

ABSTRACT: Atherosclerosis has been effectively avoided with many therapies that lower low-density lipoprotein cholesterol. However, significant cardiovascular burden remains. The effect of raising high-density lipoprotein (HDL) has been confounded by other factors (such as lowering triglycerides or LDL) and unsuccessful when attempting to solely increase HDL. Reviewing the available data, the failures of previous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylyl Cyclases
Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticholesteremic Agents

Share to Cholesterol Ester Transfer Proteins

Share to Clinical Decision-Making

Share to Esters

Share to Pharmacogenomic Testing

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 34173811
DOI: 10.1097/FJC.0000000000001093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.PMID 34173811Read ↗

CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.Semantic proximity Read ↗

Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.Semantic proximity Read ↗

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.Semantic proximity Read ↗

CETP inhibition and <i>ADCY9</i> genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.Semantic proximity Read ↗

Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?Semantic proximity Read ↗

The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?Semantic proximity Read ↗

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular diseaseSemantic proximity Read ↗

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.Semantic proximity Read ↗

HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.